Latest news with #GeorgeScorsis
Yahoo
13-06-2025
- Business
- Yahoo
Shuttle Pharmaceuticals says reverse stock split to become effective June 16
Shuttle Pharmaceuticals (SHPH) announced that the reverse stock split will become effective on June 16, at 12:01 a.m., Eastern Time. The company's common stock will continue to trade on The Nasdaq Capital Market under the existing symbol 'SHPH' and will begin trading on a split-adjusted basis when the market opens on June 16. At the effective time of the reverse stock split, every 25 shares of the company's issued and outstanding common stock will be automatically reclassified and combined into 1 share of common stock. This will reduce the number of issued and outstanding shares of common stock from 26,210,037 shares to approximately 1,048,401 shares, without giving effect to rounding Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on SHPH: Disclaimer & DisclosureReport an Issue Shuttle Pharmaceuticals announces 25-for-1 proposed reverse stock split Shuttle Pharmaceuticals appoints George Scorsis as chairman Shuttle Pharmaceuticals Announces Major Salary Reductions Shuttle Pharmaceuticals Announces Leadership Changes and Meeting Outcomes Shuttle Pharma Ropidoxuridine Phase 2 trial nears 50% enrollment
Yahoo
04-06-2025
- Business
- Yahoo
Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors
GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma' or the 'Company'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Health Corp., a leading Canadian cannabis distributor. From July 2017 to February 2019, Mr. Scorsis served as the Chief Executive Officer and Director of Liberty Health Sciences. From January 2015 to April 2018, Mr. Scorsis has served as Chairman of the Board of Directors of SOL Global Investments Corp. (formerly known as Scythian Biosciences Corp.) Mr. Scorsis also currently serves as the Chairman of Entourage Health Corp. (since February 2019) and Chairman of AWAKN Life Sciences (since January 2017), both of which are publicly traded on the TSX Venture Exchange and NEO Exchange. George Scorsis, newly appointed Chairman of the Shuttle Pharma Board of Directors, commented, 'I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.' About Shuttle Pharmaceuticals Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at Safe Harbor Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well as the Company's other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Shuttle PharmaceuticalsChris Cooper Chief Executive Officer info@ Investor ContactsLytham Partners, LLCshph@ in to access your portfolio
Cision Canada
27-05-2025
- Business
- Cision Canada
Entourage Health Launches Medical Cannabis Coverage with International Brotherhood of Electrical Workers
TORONTO, May 27, 2025 /CNW/ - Entourage Health Corp. (" Entourage" or the " Company"), a Canadian producer and distributor of award-winning cannabis products, is pleased to announce its medical subsidiary Starseed Medicinal (" Starseed") has added the International Brotherhood of Electrical Workers Local 353 (" IBEW 353") to its full-service medical cannabis program. The medical cannabis program launched May 1, 2025 and provides IBEW 353 members access to a team of clinical practitioners who specialize in cannabis-based treatments. Each patient receives a personalized treatment plan tailored to their medical needs. The direct billing coverage includes Starseed's full product portfolio of capsules, oils, inhalers, sublingual's, soft-chews, patches, compounds, vaporizers, and dried flower and covers a multitude of conditions. "We congratulate and proudly welcome IBEW 353 to Entourage's leading full-service Starseed medical platform. Together, we are removing the barriers to access medical cannabis as an alternative therapy for members and providing treatment options to patients for a myriad of indications," said George Scorsis, CEO of Entourage. "Our simplified and personalized treatment plans are curated alongside our healthcare experts who carefully ensure patients have access to a portfolio of leading medical cannabis products. As a result of these widely accepted therapeutic alternatives, coupled with a seamless reimbursement process, we now have 14 locals, 5 insurance providers, and 20 clinic partnerships signed to our Starseed platform." All eligible IBEW 353 members can now access Starseed's medical cannabis program by registering as patients. The Starseed program is built around a system that brings together clinical practitioners who specialize in chronic pain management, opioid cessation, insomnia and mental health therapies. Its medical marketplace is built around a Canadian virtual pharmacy system that takes online orders and has the ability to intuitively complete the claims management process seamlessly with insurance carriers. About Entourage Health Corp. Entourage Health Corp. is the parent company of Entourage Brands Corp., a licence holder producing and distributing cannabis products for the medical and adult-use markets. The Company owns and operates a fully licensed 26,000 sq. ft. Aylmer, ON processing facility. With its Starseed Medicinal medical-centric brand, Entourage has expanded its multi-channelled distribution strategy. Starseed's industry-first, exclusive partnership with the LiUNA Pension Fund of Central and Eastern Canada, the largest construction union in Canada, along with employers and union groups, complements Entourage's direct sales to medical patients. Entourage's elite adult-use product portfolio includes Color Cannabis, Saturday Cannabis – and now Dime Bag and Syndicate – sold across eight provincial distribution agencies. Entourage is the exclusive Canadian producer and distributor of award-winning U.S.-based wellness brand Mary's Medicinals, sold in both medical and adult-use channels. Forward Looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon Entourage's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified using forward-looking terminology such as "expect," "likely," "may," "will," "should," "intend," "anticipate," "potential," "proposed," "estimate" and other similar words, or statements that certain events or conditions "may," "would" or "will" happen, or by discussions of strategy. The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions, and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital; the cannabis industry in Canada generally; the ability of Entourage to implement its business strategies; and other risks. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Entourage does not undertake any obligation to update or revise any forward-looking information. New factors emerge from time to time, and it is not possible for Entourage to predict all such factors. SOURCE Entourage Health Corp.
Yahoo
27-05-2025
- Business
- Yahoo
Entourage Health Launches Medical Cannabis Coverage with International Brotherhood of Electrical Workers
TORONTO, May 27, 2025 /CNW/ - Entourage Health Corp. ("Entourage" or the "Company"), a Canadian producer and distributor of award-winning cannabis products, is pleased to announce its medical subsidiary Starseed Medicinal ("Starseed") has added the International Brotherhood of Electrical Workers Local 353 ("IBEW 353") to its full-service medical cannabis program. The medical cannabis program launched May 1, 2025 and provides IBEW 353 members access to a team of clinical practitioners who specialize in cannabis-based treatments. Each patient receives a personalized treatment plan tailored to their medical needs. The direct billing coverage includes Starseed's full product portfolio of capsules, oils, inhalers, sublingual's, soft-chews, patches, compounds, vaporizers, and dried flower and covers a multitude of conditions. "We congratulate and proudly welcome IBEW 353 to Entourage's leading full-service Starseed medical platform. Together, we are removing the barriers to access medical cannabis as an alternative therapy for members and providing treatment options to patients for a myriad of indications," said George Scorsis, CEO of Entourage. "Our simplified and personalized treatment plans are curated alongside our healthcare experts who carefully ensure patients have access to a portfolio of leading medical cannabis products. As a result of these widely accepted therapeutic alternatives, coupled with a seamless reimbursement process, we now have 14 locals, 5 insurance providers, and 20 clinic partnerships signed to our Starseed platform." All eligible IBEW 353 members can now access Starseed's medical cannabis program by registering as patients. The Starseed program is built around a system that brings together clinical practitioners who specialize in chronic pain management, opioid cessation, insomnia and mental health therapies. Its medical marketplace is built around a Canadian virtual pharmacy system that takes online orders and has the ability to intuitively complete the claims management process seamlessly with insurance carriers. About Entourage Health Corp. Entourage Health Corp. is the parent company of Entourage Brands Corp., a licence holder producing and distributing cannabis products for the medical and adult-use markets. The Company owns and operates a fully licensed 26,000 sq. ft. Aylmer, ON processing facility. With its Starseed Medicinal medical-centric brand, Entourage has expanded its multi-channelled distribution strategy. Starseed's industry-first, exclusive partnership with the LiUNA Pension Fund of Central and Eastern Canada, the largest construction union in Canada, along with employers and union groups, complements Entourage's direct sales to medical patients. Entourage's elite adult-use product portfolio includes Color Cannabis, Saturday Cannabis – and now Dime Bag and Syndicate – sold across eight provincial distribution agencies. Entourage is the exclusive Canadian producer and distributor of award-winning U.S.-based wellness brand Mary's Medicinals, sold in both medical and adult-use channels. Follow Entourage and its brands on LinkedIn Instagram: Color Cannabis, Saturday Cannabis, Starseed, Syndicate, Dime Bag Forward Looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon Entourage's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified using forward-looking terminology such as "expect," "likely," "may," "will," "should," "intend," "anticipate," "potential," "proposed," "estimate" and other similar words, or statements that certain events or conditions "may," "would" or "will" happen, or by discussions of strategy. The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions, and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital; the cannabis industry in Canada generally; the ability of Entourage to implement its business strategies; and other risks. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Entourage does not undertake any obligation to update or revise any forward-looking information. New factors emerge from time to time, and it is not possible for Entourage to predict all such factors. SOURCE Entourage Health Corp. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
04-04-2025
- Business
- Globe and Mail
Entourage Health Corp. Announces Closing of Plan of Arrangement
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (the ' Company ' or ' Entourage ') is pleased to announce the closing of the previously announced plan of arrangement (the ' Arrangement ') pursuant to which 1001095275 Ontario Inc. (the ' Purchaser '), a related party of LiUNA Pension Fund of Central and Eastern Canada (' LiUNA '), acquired, with an effective date of March 31, 2025 (the ' Effective Date '), all of the issued and outstanding common shares of the Company (the ' Common Shares ') for cash consideration equal to C$0.005 per Common Share (the ' Consideration '). The Arrangement also provided for the same Consideration to be paid to holders of certain vested convertible securities of the Company. In addition, in connection with the Arrangement, the Company previously entered into debt settlement agreements (the ' Debt Settlement Agreements ') with holders of C$1,013,050 in aggregate principal amount of unsecured debentures issued by a subsidiary of the Company (the ' Unsecured Debentures '). The Debt Settlement Agreements provided for the full and final settlement of the Unsecured Debentures in exchange for an aggregate cash payment of C$250,000 to the holders of the Unsecured Debentures, which was completed concurrently with closing of the Arrangement. The Arrangement was approved by the Company's shareholders (the ' Shareholders ') on March 21, 2025 and by the Superior Court of Justice (Commercial List) on March 26, 2025. 'Today marks a new chapter for Entourage as we complete this transaction alongside LiUNA,' commented George Scorsis, CEO of Entourage. 'This important milestone highlights the strength of our business, the dedication of our team, and the opportunities that lie ahead. We are grateful for LiUNA's continued support—their commitment has been instrumental in reaching this point. We look forward to building on this partnership as we drive the next phase of growth and continue delivering high-quality products to consumers and patients.' With the Arrangement now complete, Entourage intends to cause the Common Shares to be delisted from the TSX Venture Exchange (the ' TSX-V '), Frankfurt Stock Exchange and OTC Markets as soon as reasonably practicable. In connection therewith, Entourage intends to submit an application to the applicable securities regulators to cease to be a reporting issuer and to terminate its public reporting obligations. As at the Effective Date, each Shareholder is entitled to receive the Consideration per Common Share. To receive their respective Consideration, registered Shareholders must surrender the certificates representing their Entourage securities together with a duly completed and corresponding executed Letter of Transmittal to TSX Trust Company. The Letter of Transmittal was mailed to Shareholders with Entourage's management information circular dated February 10, 2025. If you have any questions or require further information about the procedures to complete your Letter of Transmittal, please contact TSXT at 1-866-600-5869 (toll-free in North America) or 416-361-0930 (outside North America) or by email at tsxtis@ The Letter of Transmittal, applicable to each Shareholder, is for use by registered Shareholders only and is not to be used by beneficial holders of Common Shares (' Beneficial Shareholders '). A Beneficial Shareholder does not hold Common Shares in its name but such shares are held by an intermediary such as a brokerage firm, or clearing agency such as CDS. If you are a Beneficial Shareholder, your intermediary will submit the required documentation in order to receive your consideration. A copy of the Purchaser's early warning report will be filed on the Company's profile on SEDAR+ at and available upon request by contacting Investor@ About Entourage Health Corp. Entourage Health Corp. is the publicly traded parent company of Entourage Brands Corp., a licence holder producing and distributing cannabis products for the medical and adult-use markets. The Company owns and operates a fully licensed 26,000F sq. ft. Aylmer, ON processing facility. With its Starseed Medicinal medical-centric brand, Entourage has expanded its multi-channelled distribution strategy. Starseed's industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, along with employers and union groups, complements Entourage's direct sales to medical patients. Entourage's elite adult-use product portfolio includes Color Cannabis, Saturday Cannabis – and now Dime Bag and Syndicate – sold across eight provincial distribution agencies. Exclusive Canadian producer and distributor of award-winning U.S.-based wellness brand Mary's Medicinals, sold in both medical and adult-use channels. For additional information or investor or media inquiries: 1-888-385-5003 Investor@ About LiUNA Pension Fund of Central and Eastern Canada Established in 1972, the LiUNA Pension Fund of Central and Eastern Canada (LPFCEC) is one of the fastest growing multi-employer pension funds across Canada. With a diverse investment portfolio and over $12 billion in assets, LPFCEC has yielded positive returns for the plan, and has created many needed institutions across North America through a broad range of investments. Learn more at Forward-looking statements and forward-looking information Certain statements made herein, including statements relating to matters that are not historical facts and statements of the Company's beliefs, intentions and expectations about developments, results and events which will or may occur in the future, constitute 'forward-looking information' within the meaning of applicable Canadian securities legislation. Forward-looking information relates to future events or future performance, reflect current expectations or beliefs regarding future events and is typically identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'intend', 'likely', 'may', 'plan', 'seek', 'should', 'will' and similar expressions suggesting future outcomes or statements regarding an outlook. Forward-looking information includes, but is not limited to, statements with respect to the Arrangement, including the expected de-listing of the Common Shares and the Company ceasing to be a reporting issuer and other statements that are not historical facts. Forward-looking information is based upon certain assumptions and other important factors that, if untrue, could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such information. There can be no assurance that such information will prove to be accurate. Such information is based on numerous assumptions, including assumptions regarding present and future business strategies, local and global economic conditions, and the environment in which the Company operates. Although the Company believes that the forward-looking information in this news release is based on information and assumptions that are current, reasonable and complete, this information is by its nature subject to a number of factors, many of which are beyond the Company's control, that could cause actual results to differ materially from management's expectations and plans as set forth in such forward-looking information, including, without limitation, the following factors, many of which are beyond the Company's control and the effects of which can be difficult to predict: (a) the possibility of adverse reactions or changes in business relationships resulting from the completion of the Arrangement; (b) the possibility of litigation relating to the Arrangement; (c) risks related to the diversion of management's attention from the Company's ongoing business operations; and (d) other risks inherent to the Company's business and/or factors beyond its control which could have a material adverse effect on the Company. The Company cautions that the foregoing list is not exhaustive of all possible factors that could impact the Company's results. Readers are cautioned not to place undue reliance on forward-looking information. By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties, both general and specific, which contribute to the possibility that the predicted outcomes will not occur. Events or circumstances could cause the Company's actual results to differ materially from those estimated or projected and expressed in, or implied by, this forward-looking information. Investors and others should carefully consider the foregoing factors, other uncertainties and potential events and the risk factors and other cautionary statements in Entourage's disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR+ at and should not rely on the Company's forward-looking information to make decisions with respect to the Company. Furthermore, the forward-looking information contained herein are made as of the date of this document and the Company does not undertake any obligation to update or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. All forward-looking information contained herein is expressly qualified by this cautionary statement.
